Celularity Inc. GXGX
10.20 +10.20
Day range unavailable
52-week range unavailable
Financial health
Altman Z-Score
-8.29 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -2.8×
FY 2019 5y median -2.8× FY 2025
P/S 9.8×
FY 2019 5y median 4.1× FY 2025
P/B -6.9×
FY 2019 5y median 0.3× FY 2025
P/FCF -19.7×
FY 2019 5y median -34.0× FY 2025
EV/EBITDA 44.3×
FY 2019 5y median 24.8× FY 2025
EV/Sales 12.2×
FY 2019 5y median 0.0× FY 2025
FCF Yield -5.1%
FY 2019 5y median -1.4% FY 2025
Profitability
Gross Margin 76.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin -230.9%
FY 2019 5y median -70.7% FY 2025
Net Margin -345.8%
FY 2019 5y median -106.8% FY 2025
ROE 241.2%
FY 2019 5y median 0.0% FY 2025
ROIC -169.7%
FY 2019 5y median -47.1% FY 2025
ROA -85.5%
FY 2019 5y median -43.6% FY 2025
Growth (YoY)
Revenue -51.0%
FY 2019 FY 2025
Operating Income -59.8%
FY 2019 FY 2025
EPS (diluted) -36.0%
FY 2019 FY 2025
Free Cash Flow -102.0%
FY 2019 FY 2025
Financial Health
Current Ratio 0.2×
FY 2019 5y median 0.2× FY 2025
Quick Ratio 0.1×
FY 2019 5y median 0.1× FY 2025
Debt / Equity -1.8×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 8.5×
FY 2019 5y median 0.0× FY 2025
Interest Coverage 9.1×
FY 2019 5y median 6.1× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio -0.1%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
